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Correction

Correction: Secukinumab in the treatment of psoriatic
arthritis: efficacy and safety results through 3 years from
the year 1 extension of the randomised phase III FUTURE 1
trial
Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab in the treatment of psoriatic
arthritis: efficacy and safety results through 3 years from the year 1 extension of the
randomised phase III FUTURE 1 trial. RMD Open 2018;4:e000723. doi: 10.1136/
rmdopen-2018-000723corr1
The authors noticed a potential data inconsistency in the published version. The
statement regarding the tuberculosis needs to be updated in the first paragraph of
the ‘Safety’ sub-section under the ‘Results’ section (page 4).
The corrected information on tuberculosis is: No new cases of tuberculosis, and
noreactivation of latent tuberculosis were reported.
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